Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment.

Pharmaceutics · 2022 · PMC9865370 · PMID 36678756

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep = 0.07so close (0.05 < p ≤ 0.1)

A doubling of overall response rate at 12 weeks was observed in the combination therapy arm compared to monotherapy, but it did not reach statistical significance ( p = 0.07).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.